Lv51
988 积分 2023-04-23 加入
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies
4小时前
待确认
Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide
4小时前
已完结
Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives
4小时前
待确认
Nanoinducer-mediated mitochondria-selective degradation enhances T cell immunotherapy against multiple cancers
4小时前
已完结
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors
4小时前
已完结
Cell Surface‐Tethered Nucleic Acid Therapeutics Program Robust and Tumor‐Responsive Enhancement of Adoptive Cell Therapy
4小时前
已完结
Enrichment of CD7+CXCR3+ CAR T cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma
4小时前
已完结
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
4小时前
已完结
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges
4小时前
已完结
Effective use of anti-CD19 chimeric antigen receptor T cells in a case of treatment-resistant granulomatosis with polyangiitis
4小时前
已完结
皖公网安备34019202002308
